Galapagos NV (GLPG) is a publicly traded Healthcare sector company. As of May 21, 2026, GLPG trades at $27.73 with a market cap of $1.83B and a P/E ratio of 0.00. GLPG moved -3.89% today. Year to date, GLPG is -14.31%; over the trailing twelve months it is +7.48%. Its 52-week range spans $22.36 to $37.78. Analyst consensus is sell with an average price target of $25.00. Rallies surfaces GLPG's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Galapagos to Share $1.675B Ouro Medicines Acquisition Costs for 20–23% Royalties: Galapagos will fund half of Gilead’s $1.675 billion upfront payment and up to $500 million in milestone payments to acquire Ouro Medicines, absorbing its operating assets and retaining its team. The agreement secures Galapagos a 20–23% royalty on global net sales of OM336 and frees €500 million for share repurchases or other uses.
| Metric | Value |
|---|---|
| Price | $27.73 |
| Market Cap | $1.83B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $37.78 |
| 52-Week Low | $22.36 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
2 analysts cover GLPG: 0 strong buy, 0 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is sell. Average price target: $25.00.